Journal article
Preferences for breast cancer prevention among women with aBRCA1orBRCA2mutation
Carol A Mansfield, Kelly A Metcalfe, Carrie Snyder, Geoffrey J Lindeman, Joshua Posner, Sue Friedman, Henry T Lynch, Steven A Narod, D Gareth Evans, Alexander Liede
Hereditary Cancer in Clinical Practice | BMC | Published : 2020
Abstract
Background: Women with a BRCA1 or BRCA2 mutation have high lifetime risks of developing breast and ovarian cancer. The decision to embark on risk reduction strategies is a difficult and personal one. We surveyed an international group of women with BRCA mutations and measured choices and sequence of breast cancer risk reduction strategies. Methods: Women with a BRCA1/2 mutation and no previous cancer diagnosis were recruited from the US, Canada, the UK, Australia, and from a national advocacy group. Using an online survey, we asked about cancer-risk reduction preferences including for one of two hypothetical medicines, randomly assigned, and women's recommendations for a hypothetical woman (..
View full abstractGrants
Awarded by Amgen Inc. (Thousand Oaks, California, USA)
Awarded by National Health and Medical Research Council (Australia) Fellowship
Awarded by NIHR Manchester Biomedical Research Centre
Funding Acknowledgements
RTI Health Solutions received funding from Amgen Inc. (Thousand Oaks, California, USA) for this study (study no. 20140153). This publication was also supported by revenue from Nebraska's excise tax on cigarettes awarded to Creighton University through the Nebraska Department of Health & Human Services (DHHS). Its contents represent the views of the authors and do not necessarily represent the official views of the State of Nebraska or DHHS. Funding was also received from the Liz's Legacy fund through Kicks for a Cure. Dr. Henry Lynch's work was partially funded through the Charles F. and Mary C. Heider Chair in Cancer Research, which he held at Creighton University. Dr. G Lindeman is supported by a National Health and Medical Research Council (Australia) Fellowship (1078730, 1175960). Dr. D Gareth Evans is supported by the NIHR Manchester Biomedical Research Centre (ISBRC-1215-20007).